We, like many others, wish to use modern molecular methods to alter neuronal functionality in primates. For us, this requires expression in a large proportion of the targeted cell population. Long generation times make germline modification of limited use. The size and intricate primate brain anatomy poses additional challenges. We surved methods using lentiviruses and serotypes of adeno-associated viruses (AAVs) to introduce active molecular material into cortical and subcortical regions of old-world monkey brains. Slow injections of AAV2 give well-defined expression of neurons in the cortex surrounding the injection site. Somewhat surprisingly we find that in the monkey the use of cytomegalovirus promoter in lentivirus primarily targets glial cells but few neurons. In contrast, with a synapsin promoter fragment the lentivirus expression is neuron specific at high transduction levels in all cortical layers. We also achieve specific targeting of tyrosine hydroxlase (TH)-rich neurons in the locus coeruleus and substantia nigra with a lentvirus carrying a fragment of the TH promoter. Lentiviruses carrying neuron specific promoters are suitable for both cortical and subcortical injections even when injected quickly.
INTRODUCTION
Modern molecular methods allow the introduction of exogenous genetic material into cells with the goal of altering cellular function. A large number of experiments have focused on repairing cellular function with the goal of developing therapies (http://www.wiley.com/legacy/wileychi/genmed/clinical/), such as introducing a functional gene to replace a mutated gene, 1, 2 downregulating a disruptive gene 3, 4 or adding protective properties to cells affected by disease. 5 For those interested in studying information processing in the nervous system, a parallel effort is underway to introduce agents into developed neurons to allow control over neuronal activity via optical or chemical methods. [6] [7] [8] In experimental settings such agents can provide a means to connect cellular mechanisms and activity to brain function [9] [10] [11] and in clinical settings could eventually offer an opportunity to ameliorate or even cure neuronal disorders attributed to failures in normal brain activity. 12 To repair cellular function it is often adequate or even desirable to target whole organs, such as the lung 13 or the whole brain. 14 To manipulate neural activity selectively, it is necessary to deliver the genetic material to a specific cell population often into a particular local brain region with a high rate of transduction (penetrance). To reach this goal we must identify agents and techniques for controlling delivery and expression in the targeted brain region or specific neuron populations. To date some of the most successful experiments in this regard are those done in rodents making use of germline modification. 10, [15] [16] [17] Confining expression to a specific area and cell type has been challenging in old-world monkeys, the experimental animal whose brain structure is most similar to humans. In old-world monkeys, germline modification is not practical because of long generation times. There are also limitations in the number of animals available for any single study.
Replication-deficient viruses can be used to deliver molecularly active agents into developed central nervous system neurons in vivo. 18 The two most widely applied viruses in nonhuman primates are adeno-associated virus (AAV) 19 and lentivirus. 20 A single injection via convection-enhanced delivery of AAV into striatum and thalamus is followed by transgene expression in a large volume of tissue. 21, 22 However, in brain structures that are not spherical, such as the cortical sheet or in a deep nucleus, such as the substantia nigra (SN), this single injection approach is not likely to work very well. Three recent reports using AAV to deliver optogenetic constructs into cortical areas of nonhuman primates highlight both the potential and the difficulties. All three had at least some success. However, populations showing expression were limited in idiosyncratic ways. AAV5 injected into motor cortex showed good penetrance (30-70%) in the deeper layers, and basically no expression in layers 1-3; there was no apparent behavioral effect even though there were easily observed alterations in neuronal activity when the material was activated. 23 AAV1 injections of an activating channel into primary visual cortex (V1) were followed by strong expression in layer 4B only; there was a light-induced behavioral and electrophysiological effect. 24 Single site AAV8 injection with an optogenetic construct into the superior colliculus was followed by expression in approximately 30% of superior colliculus neurons; this was high enough penetrance to yield modest light-induced behavioral and electrophysiological effects. 25 Han et al. 26 used lentivirus transduction with a promoter specific to pyramidal cells but did not further report data on the extent of the expressing area.
Although the idiosyncrasies described above will be important for targeting specific layers of cortex, it would be good to have a means of expressing the desired gene product in most neurons throughout a targeted region. For our purpose, which is to control neuronal activity, it will be necessary to achieve uniform coverage for neurons in a specified region of the cortex or to target neuron populations in deeper regions of the brain. Here we report the results of a survey intended to identify a set of injection techniques and viral construct backbones that yield confined tissue coverage and high penetrance. Our experiments were not intended as an extensive set of parametric studies, but rather they were an effort to develop techniques that provide the means of expressing molecular components to manipulate neuronal activity in rhesus monkeys. To this end, we used several AAV and lentivirus serotypes, different promoters and several variations in injection technique. In an example of how variably constructs can behave when packaged in different viruses, we find that expression from a cytomegalovirus (CMV) promoter is neuron specific in several AAV serotypes but when the CMV promoter is packaged into lentivirus the protein expression is found primarily in glial cells. In our efforts to improve the targeting in specific brain regions, we were able to use AAV2 effectively. The material selectively targeted neurons and the spread of the material was moderate making it easy to estimate how to keep it confined to the targeted tissue. Lentivirus with a synapsin promoter expresses in all layers of the cortex at high penetrance and a 3.1 kb fragment of the primate tyrosine hydroxylase (TH) promoter results in specific expression in noradrenergic neurons in the locus coeruleus (LC) and in dopaminergic neurons in the SN respectively.
RESULTS

Testing injection parameters for AAV serotypes in visual and motor cortices
To identify an AAV serotype, that would show high local neuron penetrance and achieve expression across a controllable extent of cortex, for example, within a single architectonic region, we surveyed several vectors made with different AAV serotypes expressing a green fluorescent protein (GFP) from a CMV promoter. The serotypes AAV1, AAV2, AAV6, AAV8, AAV9, AAV10Rh were used because they were available as stock vectors at the PENN Vector Core at the University of Pennsylvania Gene Therapy Program, several of which have been previously tested in rodents. 27 Virus titers were standardized to 10E13 particles/ml, with exception to AAV2, which was supplied at a titer of 5 Â 10E12. We surveyed injection speeds from 100-2000 nl min À 1 and volumes from 1ml-5 ml into motor cortex and visual cortex using a motorized pump. The syringes were held in a standard stereotaxic device mounted on a computer-controlled pump. The needle was inserted quickly to penetrate the pia and then positioned to the desired injection depth.
There was an inverse relation between injection speed and virus spread. The slower the injection speed, the larger the volume of covered tissue relative to volume of virus injected. 500 nl min À 1 and a volume of 2 ml of virus suspension per injection appear to be a good compromise between limiting the length of surgery time and cortical volume covered by virus expression from one injection. All serotypes with the exception of AAV8 showed a spread of at least 2 mm from the injection sites in both cortical tissues using these parameters. AAV2 and AAV6 had a good combination of well-defined edges and neuronal selectivity. Spread from a single injection ranged from 2 to 4 mm. These agents make it possible to cover substantial and controllably sized areas by injecting multiple sites as we did for motor cortex (Figures 1a-e, AAV6 ) and visual cortex (Figures 1f-j, AAV2 ) respectively. From gross examination, other serotypes seemed less suitable for neuron coverage of visual or motor cortex when compared to AAV2, therefore we did not characterize them in any detail. AAV9 and AAV10R showed a wide area coverage of up to 10 mm per injection. The spread from a single injection seemed too wide to keep expression within a confined cortical area. Also, the infection efficiency tapered off gradually from the injection site without creating a clear boundary. AAV1 showed well-defined edges of expression and seemed to have reasonably uniform expression, but there was a substantial preference for cells lacking NeuN staining, likely glial cells (Supplementary Figures  S1A and B) . In our experiments, AAV8 did not spread well, yielding low area coverage (o2 mm) in motor and visual cortex. From this initial survey, we decided that AAV2 has the best promise to achieve reasonably uniform coverage in cortex. For all serotypes, with the exception of AAV8 we saw axonal labeling and transport of GFP to the axon terminals (see Supplementary  Figures S1C-F for examples) .
Expression of the AAV2 serotype has been well characterized for injections into subcortical regions in the monkey brain. 21, 28 Here we analyzed its cortical expression. The AAV2-expressing tissue was stained for the neuron marker NeuN to look for colocalization with GFP to assess neuronal expression, 29 stained for g-aminobutyric acid (GABA) to assess expression in interneurons, 30 and stained for glial fibrillary acidic protein (GFAP) to assess glial expression. As shown in Figures 1k and l, expression was high in neurons. In the example shown, injection of a 2 ml virus suspension at 500 nl min À 1 of an AAV2 construct with GFP, we counted 483 NeuN-positive cells of 500 GFP positive cells within 500 mm of the injection site at 41% penetrance (483 GFP-expressing of 1186 total counted NeuN-positive cells), including inhibitory neurons near the injections site (Figures 1m and n) . Although there was some expression in glia (Figures 1o and p) , expression levels were generally much lower than in neurons. For AAV2, like for the other serotypes surveyed, GFP expression in neurons varied widely from injection to injection, with the range of penetrance being consistent with that seen in other studies using AAV serotypes (30-70% within 500 mm). 23 Neuron specificity and penetrance of AAV6 in the cortex was similar to AAV2. In the motor cortex we counted 274 NeuN-positive cells of 300 cells expressing GFP within 500 mm of the injection site at 36% penetrance (292 GFP-expressing of 808 total counted NeuN-positive cells). However, in the regions surveyed, we did not find any advantage of using AAV6 over AAV2, and AAV2 has the slight advantage that it has been used in other nonhuman primate studies without any reports of adverse effects. 21, 28 Our results do suggest that it should be possible to achieve reasonable levels with expression occurring primarily within neurons using AAV2, at least in the visual and motor cortices.
Handheld versus pump-driven injections of AAV2 and lentivirusexpressing ivermectin-sensitive chloride channels Because of the size, sheet-like structure and sulci, many cortical areas of the brain will require several injections to achieve uniform coverage. Stereotactically guided injections allow good control for speed and placement of injections on the lateral cortical surface but are time consuming to place. Handheld injections, in contrast, offer quick change of position from one injection site to the next, especially for areas difficult to reach, such as rhinal cortex, 31 where stereotaxic injections would require long penetrations of brain tissue. We compared handheld and stereotaxic injections for both AAV2 and lentiviral vectors in visual cortex. To test whether we could detect virally expressed membrane channels relevant for functional experiments, injection contained an equal mixture of viruses expressing fluorescent protein tagged GluCl alpha and/or beta subunits, previously used for neuronal silencing in rodents. The needle was then removed without delay and inserted into the next location for injection. This procedure was repeated several times to cover the intended cortical area in a grid-like pattern. As expected from the previous AAV survey, pump-driven infusion yielded good spread of AAV2 virus. Two injections, placed 1.5 mm apart achieved uniform coverage (Figures 2b and c), whereas with fast Handheld injections AAV2 coverage was only a few hundred micra per injection (Figures 2g and h ). Perhaps surprisingly, lentivirus showed the opposite pattern. Pump-driven injections at 500 nl min À 1 resulted in only a small area of virus coverage of a few hundred micrometer (Figures 2d and e), whereas it was clear from inspection that the Handheld injections showed more uniform coverage with higher local expression levels (Figures 2i and j). We did not find any obvious preference for specific cortical layers for either lentivirus or AAV2, as GFP-expressing cells were found in all layers. Thus in our hands to achieve usable spread of lentivirus requires fast injection speeds. Handheld injections of lentivirus seem promising for covering large cortical areas, particularly in regions that would be difficult to cover with stereotaxic injections. 
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Lentivirus expression from a CMV promoter is expressed in dopamine receptor D2-positive cells but shows strong glial cell preference A promising application for molecular tools is to target specific cell types by either controlling expression or by targeting a functional cellular component. As an example for the latter, RNA interference by injection of dopamine receptor D2 antisense expressing DNA plasmid into rhinal cortex has been used to temporarily change a cognitive behavior in the monkey. 31 We first established that we could visualize cellular dopamine receptor staining on monkey brain sections (Figures 3a-e, see also Materials and Methods). Then, to test whether we can target DRD2 neurons with viral vector constructs, we injected AAV2 carrying a cyan fluorescent protein (CFP) tagged membrane receptor construct (AAV-CMV::GluCla-CFP) 32 into the left rhinal cortex (Figures 3e-g ) and a RNA interference lentivirus construct with a GFP reporter (pGIPZ-CMV-GFP) into the right rhinal cortex (Figures 3e and h-i) using the handheld injection method.
Both, AAV2 and lentivirus expressed GFP derivatives showed partial overlap with DRD2 expressing cells in rhinal cortex (Figures 3a-d and j-m) . Based on visual inspection, AAV2 staining for GFP was generally observed in cells with stronger expression levels of DRD2, whereas lentivirus staining for GFP showed colabeling in cells with lower but detectable levels of expression of DRD2. On further analysis we found that the AAV2 expression was almost exclusively neuronal (GluCl-CFP expression colocalized with the neuronal marker NeuN; Figures 3h and i), whereas lentivirus expression from the pGIPZ-CMV-GFP construct expressed strongly in GFAP-positive gilal cells and only in a very limited number of neuronal cells (Figures 3k-n) . To exclude the possibility that this bias is because of the pGIPZ backbone, we tested our Lenti-CMV:: GluCla-CFP construct, which has a different backbone and observed the same glial cell specificity (Figures 3p and q) .
From these results it appears that packaging the CMV promoter into lentivirus conveys a strong bias toward infecting glial cells in monkeys independent of vector backbone.
Lentivirus expression from a synapsin promoter is specific to neurons in all six layers of the visual cortex Lentivirus can carry a substantially larger packaging load than AAV, 33 providing more flexibility for using larger promoter fragments or design of inducible constructs. 3 It is also easier to produce in-house to high-grade in vivo titers. 34 In earlier experiments, we showed that lentivirus spreads better in handheld injections than in slow stereotaxic infusions. However, stereotaxic injections have the potential to provide better control over speed and volume when covering cortical areas. Therefore, we modified the lentiviral expression vector to express GFP from a synapsin promoter fragment and tested micropump-driven injections at a relatively high rate of 2 ml min À 1 into the visual cortex to determine whether the synapsin promoter would convey neuronal specificity to the lentivirus constructs. Injections were set approximately 3 mm apart from each other.
All neuron layers of V1 showed expression in an area of approximately 1 mm around the needle track (Figures 4a-c) . Expressing cells were confined to a specific region around the injection site with the number of GFP positive cells falling sharply off this region (Figure 4d) . Out of 1362 NeuN-positive cells counted on confocal sections within 750 mm of one injections site 1178 were GFP positive, putting the penetrance at 86%. There were only 19 cells (1.3%) GFP positive cells within this region, which had no detectable NeuN expression (Figure 4e ), whereas there was colabeling of GFP with GABA positive interneurons (Figure 4f ), we did not find any evidence of GFP expression in Glia by staining sections with antibodies for the GFAP protein (Figure 4g) .
Thus, injections of a construct using a backbone of lentivirus with the synapsin promoter led to expression in a majority of neurons within 750 mm radius of the injection site. Therefore, a stereotaxic injection matrix with a distance of 1.5 mm at a speed of 2 ml min À 1 should be sufficient to achieve cortical coverage with a lentiviral synapsin construct.
Lentivirus expression from a TH promoter is specific to noradrenergic cells in the LC and to dopaminergic cells in the SN We injected a lentivirus containing a 3.1 kb proximal promoter fragment of the rhesus monkey TH promoter driving expression of GFP bilaterally into the SN of two monkeys. In one of these monkeys we also injected the LC on both sides. From histological analysis of whole brain sections we saw that expression of GFP was confined to the same general area as TH expression on consecutive sections for both LC (Figures 5a-d) and SN (Figures  5e-g) . Using confocal microscopy to analyze the expression area on a cellular level on double-stained sections (Figures 5h-l 
DISCUSSION
To use molecular tools to modify neuronal function in large, complicated brains such those of primates and humans, it is going to be necessary to introduce the materials into mature neurons safely and efficiently. Germline modification, a method often used to gain specificity for these tools in rodents, is impractical in nonhuman primates, especially in old-world monkeys, which are expensive to breed, have long gestation times (on the order of 6 months), and slow development for reaching sexual and Virus injection techniques for primate CNS W Lerchner et al behavioral maturity (3-5 years) . Currently, replication-deficient viruses appear to be the most promising approach to carry the desired genes into mature neurons. We surveyed several virus serotypes, promoters and injection parameters to identify combinations with good transduction properties in the macaque brain. We identified some combinations that allow for either lentivirus or AAV serotypes to transduce neurons in delimited regions with high penetrance.
In our experiments in cortex coverage with lentivirus and AAV depended on injection speed in opposite ways. AAV spread in inverse relation to the injection speed. The slower the speed the larger the area covered with a volume injected. This may likely be due to backflow along the needle track at higher speeds. 35 When Salegio et al. 28 added a step in needle diameter 3 mm back from the tip of the cannula to prevent backflow (by simply slipping a tight fitting silicate tube onto the needle), they were able to inject AAV into the basal forebrain at much faster speeds than without a step and still had good spread of the virus. 28 Our injection speeds were generally slower than that of Salegio et al. 28 We injected into cortex where cells and extracellular matrix are much more densely packed. In contrast to AAV, lentivirus required faster injection speeds to achieve good spread. We believe that this may be due to the fivefold larger particle size than AAV, needing more pressure to spread through the densely packed tissue. It is possible that injection of lentivirus with step needles would allow for a better spread with lower speeds, by allowing pressure to buildup more slowly, but preventing the backflow along the needle track.
Several recent studies seem to show that some AAV serotypes have a preference for specific cortical layers. Diester et al., 23 found opsin expression via AAV5 predominantly in the deeper cortical layers in the motor cortex, 23 while Jazayeri et al. 24 saw expression of AAV1 only in a single cortical layer (4Cb) in striate cortex. 24 In our hands, three AAV serotypes, AAV2, AAV6 and AAV8 showed a natural preference for neurons over glial cells through the cortical layers.
AAV serotypes also showed considerable variability in the way that they spread from the injection site. This might be for a couple of reasons, including variable coat proteins and trans-synaptic transport. For the AAV2 and AAV6 serotype, which we analyzed in more detail, we did not observe any indication for trans-synaptic transport, as cellular expression of the injected material was restricted to a well-defined area around the injection site. Finally, AAV2 led to reasonable expression without obvious bias across the cortical layers. Other serotypes, such as AAV1, AAV9 and AAV RH10 resulted in a much more diffuse expression across a wide area away from the injection site. It is possible that the source of this diffuse expression occurred via retrograde or anterograde trans-synaptic transport. For our purposes this was not desirable, but for some experiments it may be of advantage to investigate these serotypes further.
AAV2 which we studied in more detail than other serotypes, showed good expression throughout all layers in both visual and motor cortices. Lentivirus containing the 500 bp synapsin promoter fragment also showed high penetrance and consistent expression in neurons of all cortical layers of the V1 visual cortex. Lentivirus expression fell off sharply 1-1.5 mm from the expression track, leading to gaps in expression when injections were 3-4 mm apart. With AAV a single track leads to wider expression. However, it appears from our results that lentivirus gives higher local penetrance, and with a grid of injections placed 1.5 mm apart there should be good contiguous expression of lentivirus in cortex.
We chose lentivirus for a more detailed characterization of cortical coverage and specific promoters, partly because of the ease of in-house production and partly because the greater packaging size allowed us to test larger promoter fragments like the TH promoter. When we used a proximal 3.1 kb fragment of the primate TH promoter in lentivirus construct expression was limited to catecholaminergic neurons. By selecting the location where the virus was injected, either the SN or the LC, this promoter fragment had expression limited in dopaminergic or noradrenergic neurons, respectively. This offers the possibility to study the effects that occur with either activation or silencing of catecholaminergic neurons.
When packaged in a AAV2 capsid, a CMV promoter drives expression primarily in neurons. However, when similar CMV promoter constructs are packaged in lentivirus, they drive expression primarily in glial cells and only a limited number of neurons, possibly GABA positive interneurons. This limited neuronal expression with CMV promoter in lentivirus is probably not due to selective virus specificity, because when a construct using a 500 bp human synapsin promoter fragment is packed in lentivirus, expression occurs almost exclusively within neurons, but not within glial cells. In the rhinal cortex we see coexpression of lentivirus CMV expressed GFP with DRD2 antibody staining and with the glia marker GFAP but not with the neuronal marker NeuN. Visual inspection suggests that GFP expression appears to be limited to a population of weaker expressing DRD2 positive cells, which may indicate a weaker DRD2 expression in glia than in neurons of the rhinal cortex. These results show that there is clearly more nonhuman primate specific characterization necessary to gain a better understanding of virus specificity and promoter fragments necessary to target specific cell populations.
Nonhuman primate brain, with sulci and large sheet-like cortical areas, poses big challenges for getting uniform high penetrance injections of viral constructs. Because of this difference in structure and likely different patterns of selectivity in viral targeting, the data from rodent experiments are not sufficient in planning injections for functional experiments in old-world monkeys. This makes surveys like ours a useful step toward gaining control of the tools for use in the primate brain. Even though this study is only a survey of various techniques, we hope it provides useful information for application and development of molecular approaches of neuronal manipulation in the monkey brain, which is essential if these techniques are ever to be used for selective experimental work in monkeys and therapeutic applications in the human.
Summary of recommendations
We conducted this survey to determine the best method to achieve viral expression at high neuronal penetrance in large but defined locations of the monkey brain. Below is a summary of parameters that we are currently using based on our results.
AAV virus injections into the open cortex.
The slower the better. We use 2 ml virus per site injected at 500 nl min À 1 to balance injection time (which increases the length of surgery) with spread of virus per injection. To cover a large area of cortex, we recommend a 1.5 mm injection matrix. Currently, we are experimenting with interlaced injections using a 2 Â 3 grid, where the needles are spaced 3 mm from each other to reduce potential tissue damage and to reduce the overall time in surgery.
Lentivirus injections into the open cortex. We have good experience with either handheld or stereotaxic injections (1 ml min À 1 virus per injection). Injections are placed approximately 1.5 mm apart. For handheld injections a finger tap is used to advance the plunger of the Hamilton syringe. This injection technique is particularly useful for deep and convoluted areas, like rhinal cortex where during surgery the lateral temporal cortex must be retracted to make the targeted area accessible.
Lentivirus injections into deep brain areas. For deep brain areas, like the SN and LC, we inject by placing the needles trough an Virus injection techniques for primate CNS W Lerchner et al implanted grid 2 mm apart from each other and let the needle rest for 10 min at the location of injection. For vertical spacing, we pull up the needle 2 mm before injecting again.
MATERIALS AND METHODS
DNA constructs
For plasmids to produce Lenti-CMV::iCla-cerulean and Lenti-iClb-venus, the coding region of previously published GluCl constructs was reoptimized and point mutation corresponding to cerulean and venus were introduced into the CFP and YFP regions. Coding regions for the plasmids were synthesized by GeneArt (Life Technologies) and cloned into the p156RRL-sinPPT-CMV-GFP-PRE/Nhe I plasmid (Addgene plasmid 17448) by replacing GFP. To create the DNA for Lenti-TH::GFP, 3.1 kb of the proximal portion of the rhesus monkey TH promoter (http://www.ncbi.nlm.nih.gov) was synthesized by GeneArt and cloned into the p156RRL-sinPPT-CMV-GFP-PRE/Nhe I plasmid by replacing the CMV promoter. Similarly, for Lenti-SYN::GFP, the proximal 500 bp of the human synapsin promoter, was synthesized by GeneArt and cloned into the p156RRL-sinPPT-CMV-GFP-PRE/ Nhe I plasmid by replacing the CMV promoter.
Virus preparation and storage
Lentivirus was produced at titers 410E9 as described by Han et al. 34 In short, 293T cells (Lenti-X Invitrogen 632180, Life Technologies) were transfected with the Lenti-backbone plasmid and packaging plasmids (Addgene, Cambridge, MA, USA). Supernatant was replaced by new medium after 24 h with Ultraculture medium (Invitrogen). Lentivirus was harvested by collecting the supernatant 48 and 72 h after transfections and spinning it at 22 000 r.p.m (Beckman S28 rotor) through a 20% sucrose cushion in phosphate-buffered saline (PBS). Virus pellet was suspended by incubation in ice-cold PBS for 1-h, carefully mixed, aliquoted and frozen on dry ice for storage at À 801C until needed for surgery. Titers were determined by preparing genomic DNA from 293T cells transduced with the Lentivirus and using quantitative PCR to compare amplification of a 150 bp lentivirus fragment with amplification of a comparable fragment of the endogenous human vasopressin receptor gene (hVAR1). AAV vectors for the AAV serotype survey were stock vectors from the PENN vector core. AAV2-GluCla and AAV2-GluClb vectors 32 were produced by the UNC vector core at titers of 10E12 units/ml. Viruses were shipped in aliquots on dry ice and stored at À 801C until needed for surgery.
Subjects
We used eight old-world nonhuman primates for this study. Two Macaca fascicularis (cynomolgus monkey) were used for the AAV serotype survey in the visual cortex. Six Macaca mulatta were used for the other studies: two for injections of AAV into motor cortex, one for comparing stereotaxic versus Handheld injections of AAV and lentivirus into the visual cortex, two for injections of AAV and lentivirus into the rhinal cortex, two for Lenti-TH injections into LC and SN and one monkey for Lenti-synapsin injections into the visual cortex. All experimental procedures conformed to the Guide for the care and use of laboratory animals 36 and were approved by the National Institute of Mental Health animal care and use committee.
Surgeries
Surgeries were performed under aseptic conditions in a fully equipped operating suite with veterinary supervision. Before surgery, animals were sedated with ketamine hydrochloride (10 mg kg À 1 , intramuscular); a surgical level of anesthesia was then induced and maintained with isoflurane gas (1-4% to effect). Body temperature, heart rate, blood pressure and expired CO 2 were monitored throughout all surgical procedures. For all cortical injection procedures, the cortex was exposed by removing a bone flap and reflection of the dura mater. Handheld injections into the rhinal cortex have been described in detail previously. 37 All virus aliquots were allowed to thaw on ice for at least 15 min and diluted with sterile PBS if required by carefully mixing by tapping the tube. If necessary, the liquid was spun to the bottom of the tube with a small bench-top centrifuge. Virus was then carefully taken up into the needles by manually raising the plunger of a Hamilton syringe. For handheld injections, a 10 ml Hamilton syringe with a 30 gauge needle was inserted into the intended area of injection by one person and a second person pressed the plunger to approximately expulse 1ml, after which the needle was removed and inserted into the next location. For stereotaxic injections, the 10 ml Hamilton syringe was mounted into a motorized nano-injector (Havard). During penetration of the pia mater and the cortical tissue to reach the injection site, the injection speed was set to 100 nl min À 1 to exert positive pressure to reduce the possibility of needle blockage. Once the target position was reached, the injection speed was adjusted to the desired injections rate. For injections into the SN and the LC, the location was determined via magnetic resonance imaging and mounting an injection chamber with grid as described previously. 38, 39 Injections were placed at a 2 mm distance from each other, either laterally via grid holes or vertically along the needle track. The needle was kept in place for 10 min after each injection before retraction.
Histology
Between 3 and 6 weeks following the injections, each monkey was deeply anesthetized with Beuthanasia solution and perfused with 1 liter of normal saline solution followed by 3 liters of 4% paraformaldehyde in 0.1 M PBS. Monkeys for the AAV serotype survey and handheld versus stereotaxic injections (Figures 1,2) were euthanized between 3 and 4 weeks after injection, all other monkeys were killed between 5 and 6 weeks after virus injections. The brains were removed and cryoprotected through a series of glycerols in 0.1 M PBS. 40 The brains were blocked in the coronal plane and then quickly frozen in À 801 C isopentane. The brain was sectioned into 40-mm slices in the coronal plan and the sections collected in 10 series. For histochemistry, sections were blocked in 5% normal goat serum and 0.3% Triton-X 100 in tris-buffered saline (TBS), incubated with primary antibody in blocking buffer, washed and, incubated with an horse radish peroxidase secondary antibody (Vector labs, Burlingame, CA, USA, PI-1000) for 90 min and visualized with a 3,3'-diaminobenzidine (DAB) reaction and optionally counterstained with thionine. For DRD1 and DRD2 DAB histochemistry the reaction was enhanced with the Vector ABC kit (Vector Labs VECTASTAIN ABC System). DRD1 and DRD2 staining throughout the brain is consistent with published expression for these receptors in the nonhuman primate 41, 42 (Figures 3a-d) . For immunofluorescence secondary rabbit and mouse antibodies were purchased from Molecular Probes (Life Technologies), spectra as indicated in the figure legends. The secondary antibody for fluorescence detection of chick anti GFP was purchased from Abcam (DyLight 488 goat anti-Ch -ab96947). See Supplementary Table T1 for primary antibody specifications, dilutions and incubation times. For three-dimensional reconstruction of AAV serotype survey, one series (1:10) of 40-mm sections were stained for GFP with DAB, the stained areas were outlined at Â 10 magnification and reconstructed using the Neurolucida software (MBF Bioscience, Williston, VT, USA). Confocal images were examined using a Zeiss Axiovert Â 200 microscope and imaged at Â 20 and Â 63 using LSM 510 inverted scanning confocal instrument. three-dimensional Z-stacks of approximately 1 mm depth individual sections were visualized using the Zeiss LSM Confocal software. All cell counts were performed on optical confocal slices to ensure colocalization of fluorescent staining.
